The FY21 Defense Appropriations Act provides funding to the Department of Defense Rare Cancers Research Program to support research of exceptional scientific merit in the area of rare cancers research.
Roswell Park Comprehensive Cancer Center and University of Rochester’s Wilmot Cancer Institute received a $2.08 million grant from NCI to research whether Black and white cancer patients respond differently to immune checkpoint inhibitors.
City of Hope scientists have developed a novel, noninvasive liquid biopsy test for detecting lymph node metastasis in individuals with high-risk T1 colorectal carcinoma.
Yale Cancer Center researchers have discovered a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases acute lymphoblastic leukemia, chronic lymphocytic leukemia, and Mantle cell lymphoma.
Yale Cancer Center Researchers have discovered a new role for the STimulator of INterferon Genes, or STING.
A test which uses artificial intelligence to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment.
FDA has granted an accelerated approval to Jemperli (dostarlimab-gxly) for adult patients with mismatch repair deficient recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen.
FDA has approved Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
FDA has granted Breakthrough Therapy designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin), based on an FDA-approved companion diagnostic assay showing at least 10% of tumor cells overexpressing FGFR2b.
European Commission has approved Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy.
